FDA Inspection 1163119 — Ambi, Inc
The FDA completed an inspection of Ambi, Inc on February 16, 2022 in Capitola, CA. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Devices.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- February 16, 2022
- Fiscal Year
- 2022
- Product Type
- Devices
- Project Area
- Postmarket Assurance: Devices
- Location
- Capitola, CA (United States)